Promomed, LLC
Quick facts
Marketed products
- Ethyl methyl hydroxypyridine succinate + Meldonium · Cardiovascular, Neurology
This combination product enhances cellular energy metabolism and reduces oxidative stress through antioxidant and cardioprotective mechanisms. - metformin+sibutramine · Endocrinology / Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity, while sibutramine suppresses appetite by inhibiting reuptake of serotonin and norepinephrine, together addressing hyperglycemia and weight management in type 2 diabetes. - sibutramine+ microcrystalline cellulose · Obesity; Weight management
Sibutramine inhibits the reuptake of norepinephrine, serotonin, and dopamine in the central nervous system, increasing satiety and reducing appetite.
Phase 3 pipeline
- Double-Stranded RNA sodium salt · Oncology
Double-stranded RNA activates pattern recognition receptors on immune cells to stimulate innate and adaptive immune responses against tumors. - Molnupiravir (Esperavir) · Infectious Disease / Virology
Molnupiravir is a nucleoside analog that induces viral mutagenesis by causing errors during viral RNA replication, leading to viral extinction.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Promomed, LLC
What are Promomed, LLC's marketed drugs?
Top marketed products include Ethyl methyl hydroxypyridine succinate + Meldonium, metformin+sibutramine, sibutramine+ microcrystalline cellulose.
What is Promomed, LLC's pipeline?
Promomed, LLC has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Double-Stranded RNA sodium salt, Molnupiravir (Esperavir).
Related
- Ethyl methyl hydroxypyridine succinate + Meldonium · Cardiovascular, Neurology
- metformin+sibutramine · Endocrinology / Diabetes
- sibutramine+ microcrystalline cellulose · Obesity; Weight management
- Sector hub: All tracked pharma companies